AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30803997 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized treatment approaches
Number of subjects: 0
Study 30803997 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of patients' preferences
Number of subjects: 0
Study 30803997 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel treatments under investigation
Number of subjects: 0
Study 30804020 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric HER-2 B-cell peptide vaccines emulsified in Montanide ISA 720VG and Nor-MDP adjuvant, administered as three inoculations every 3 weeks.
Number of subjects: 49
Study 30804030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessment using CogState Brief Battery preoperatively and postoperatively at (<3 days), 6 weeks, and 4.5 months
Number of subjects: 0
Study 30804030 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium assessment using the Confusion Assessment Method (3D-CAM) preoperatively and postoperatively
Number of subjects: 0
Study 30804739 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 0
Study 30804813 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Restriction
Number of subjects: 0
Study 30805208 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal limiting membrane flap technique
Number of subjects: 9
Study 30805405 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% sodium hyaluronate artificial tears
Number of subjects: 180
Study 30805405 — intervention group
Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate artificial tears
Number of subjects: 180
Study 30805652 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults with stroke
Number of subjects: 35
Study 30805652 — intervention group
Group type: COMPARATOR
Intervention: Older adults without stroke
Number of subjects: 35
Study 30805652 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults with stroke and poor sleep quality
Number of subjects: 35
Study 30805768 — intervention group
Group type: EXPERIMENTAL
Intervention: Network analysis of psychosocial risks
Number of subjects: 200
Study 30805768 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of unintended pregnancies and interventions for coping with unplanned pregnancies
Number of subjects: 200
Study 30805768 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated, multilevel approach to support women during pregnancy
Number of subjects: 200
Study 30805946 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (single oral dose)
Number of subjects: 31
Study 30805946 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified dosing strategy (model-based simulations)
Number of subjects: 31
Study 30805946 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (R- and S-enantiomers)
Number of subjects: 31
Study 30806013 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cue reactivity during acute abstinence in the anterior cingulate cortex (ACC)
Number of subjects: 75
Study 30806013 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-induced change in ACC activation
Number of subjects: 75
Study 30807351 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTEMI
Number of subjects: 21994
Study 30807351 — intervention group
Group type: COMPARATOR
Intervention: STEMI
Number of subjects: 21994
Study 30807407 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterosacral ligament suspension (USLS)
Number of subjects: 186
Study 30807407 — intervention group
Group type: COMPARATOR
Intervention: Robotic sacrocolpopexy (RSC)
Number of subjects: 186
Study 30807411 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal bowel control system
Number of subjects: 73
Study 30807411 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 73
Study 30807645 — intervention group
Group type: EXPERIMENTAL
Intervention: Rogaratinib
Number of subjects: 0
Study 30808084 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin initiation <24 hours after admission
Number of subjects: 3921
Study 30808084 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin initiation <48 hours after admission
Number of subjects: 3921
Study 30808208 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive-based workplace intervention (24-week duration)
Number of subjects: 225
Study 30808311 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher income households
Number of subjects: 202
Study 30808314 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 217
Study 30808583 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d) with Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 50
Study 30808770 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced ultrasound techniques (microbubbles, elastography, ultrafast Doppler, 3D/4D imaging, high-frequency imaging)
Number of subjects: 0
Study 30809137 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal direct current stimulation
Number of subjects: 0
Study 30809137 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30809184 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Number of subjects: 20
Study 30809184 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 20
Study 30809591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal tetanus antitoxin and human intramuscular treatment
Number of subjects: 0
Study 30809591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal tetanus antitoxin and equine intramuscular treatment
Number of subjects: 0
Study 30809591 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure and human intramuscular treatment
Number of subjects: 0
Study 30809591 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure and equine intramuscular treatment
Number of subjects: 0
Study 30809725 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing and resistance exercise training for 3 months
Number of subjects: 33
Study 30809762 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational 4 mm × 32G pen needle (BD Nano™ 2nd Gen)
Number of subjects: 150
Study 30810343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment PET parameters (FDG-PET/CT)
Number of subjects: 93
Study 30810343 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV negative tumor, N3 lymph node stage
Number of subjects: 93
Study 30810343 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HPV with PET parameters (MTV, TLG, ZMP)
Number of subjects: 93
Study 30810343 — intervention group
Group type: EXPERIMENTAL
Intervention: PET 2 weeks into treatment
Number of subjects: 93
Study 30810343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment PET parameters
Number of subjects: 93
Study 30810343 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in PET parameters from pre- to mid-treatment
Number of subjects: 93
Study 30810536 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Stepped Care intervention (n=110)
Number of subjects: 220
Study 30810536 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Standard Care (n=110)
Number of subjects: 220
Study 30810536 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Stepped Care intervention
Number of subjects: 220
Study 30810536 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Standard Care
Number of subjects: 220
Study 30810593 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTR-FAP patients
Number of subjects: 160
Study 30811063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab associated with cisplatin and 5-fluorouracil
Number of subjects: 28
Study 30811063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 28
Study 30811085 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 59
Study 30811103 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Birth Weight (LBW)
Number of subjects: 2935
Study 30811103 — intervention group
Group type: EXPERIMENTAL
Intervention: High Birth Weight (HBW)
Number of subjects: 2935
Study 30811142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tavaborole 5% topical solution applied once daily to all affected toenails for 48 weeks
Number of subjects: 0
Study 30811142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tavaborole 5% topical solution applied for the first 28 days to all 10 toenails and ≤2 mm of surrounding skin in a maximal-use subgroup (aged 12 to <17 years)
Number of subjects: 0
Study 30811285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu5F9-G4 (5F9) antibody at a priming dose of 1 mg/kg followed by maintenance doses of 3 to 45 mg/kg weekly
Number of subjects: 62
Study 30811335 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30811388 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial visit stigma assessment
Number of subjects: 859
Study 30811388 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up stigma assessment
Number of subjects: 859
Study 30811388 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall change in stigma over 18 months
Number of subjects: 859
Study 30811388 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level impact on stigma
Number of subjects: 859
Study 30811388 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to medical care impact on stigma
Number of subjects: 859
Study 30811388 — intervention group
Group type: EXPERIMENTAL
Intervention: Age impact on stigma
Number of subjects: 859
Study 30811399 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model using LMP, birth weight, twin delivery, maternal height, hypertension in labor, and HIV serostatus.
Number of subjects: 468
Study 30811399 — intervention group
Group type: COMPARATOR
Intervention: New Ballard Score (NBS), last menstrual period (LMP), and birth weight used individually.
Number of subjects: 468
Study 30811475 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-lymphocyte count ratio (NLCR)
Number of subjects: 664
Study 30811475 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 664
Study 30811475 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 664
Study 30811475 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell (WBC) count, neutrophil count, lymphocyte count
Number of subjects: 664
Study 30811537 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa 2 mg/kg three times/week or 1 mg/kg six times/week subcutaneously
Number of subjects: 69
Study 30811537 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa
Number of subjects: 69
Study 30811542 — intervention group
Group type: EXPERIMENTAL
Intervention: MC4R mutations identified in children with severe early-onset obesity (8 rare mutations, 2.6%)
Number of subjects: 312
Study 30811542 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with MC4R mutations
Number of subjects: 312
Study 30811542 — intervention group
Group type: COMPARATOR
Intervention: Children without MC4R mutations
Number of subjects: 312
Study 30813812 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-vessel FFR in women (0.89±0.10)
Number of subjects: 1136
Study 30813812 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-vessel FFR in women (2.72±0.13)
Number of subjects: 1136
Study 30813812 — intervention group
Group type: EXPERIMENTAL
Intervention: Total anatomical and physiologic disease burdens
Number of subjects: 1136
Study 30813812 — intervention group
Group type: COMPARATOR
Intervention: Sex influence on total disease burden
Number of subjects: 1136
Study 30813845 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g OGTT
Number of subjects: 100
Study 30813845 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 100
Study 30813845 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g OGTT
Number of subjects: 100
Study 30813927 — intervention group
Group type: EXPERIMENTAL
Intervention: Th2/Th1 ratio
Number of subjects: 71
Study 30813927 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently increasing Th2/Th1
Number of subjects: 71
Study 30813927 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 71
Study 30813927 — intervention group
Group type: COMPARATOR
Intervention: Critically ill patients without severe sepsis
Number of subjects: 71
Study 30813942 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE quantification by FWHM
Number of subjects: 670
Study 30813942 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE quantification by 2-SD
Number of subjects: 670
Study 30813942 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE quantification by 3-SD
Number of subjects: 670
Study 30813942 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE-VPS
Number of subjects: 670
Study 30813942 — intervention group
Group type: EXPERIMENTAL
Intervention: FWHM
Number of subjects: 670
Study 30813942 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-SD
Number of subjects: 670
Study 30814321 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (16 mg) plus hydrochlorothiazide (12.5 mg)
Number of subjects: 2361
Study 30814321 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg)
Number of subjects: 2361
Study 30814321 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Candesartan plus Hydrochlorothiazide and Rosuvastatin)
Number of subjects: 2361
Study 30814321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2361
Study 30814647 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological markers including Neurofilament light chain, phosphorylated heavy chain, 8-oxo-2'-desoxyguanosine, 4-hydroxy-2-nonenal, isoprostane, interleukin-6, ferritin, hepcidin, transferrin
Number of subjects: 512
Study 30814647 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite scores of identified biomarkers in association with established clinical predictors
Number of subjects: 512
Study 30815001 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 Tat vaccination
Number of subjects: 0
Study 30815001 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30815467 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood and sputum sampling monthly and at exacerbation to detect respiratory infections and eosinophilic inflammation
Number of subjects: 127
Study 30815468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)
Number of subjects: 16417
Study 30815468 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI)
Number of subjects: 16417
Study 30815468 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FF/VI
Number of subjects: 16417
Study 30815468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16417
Study 30815468 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids and one or more bronchodilators prior to study entry
Number of subjects: 16417
Study 30815590 — intervention group
Group type: EXPERIMENTAL
Intervention: Family talk intervention (FTI) consisting of six meetings with the family, led by two interventionists.
Number of subjects: 0
Study 30815589 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery before pregnancy
Number of subjects: 0
Study 30815589 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention during pregnancy
Number of subjects: 0
Study 30815589 — intervention group
Group type: COMPARATOR
Intervention: Obese women without any intervention
Number of subjects: 0
Study 30815589 — intervention group
Group type: COMPARATOR
Intervention: Normal weight women
Number of subjects: 0
Study 30815984 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted genetic risk score (wGRS) for CYP2A6 including seven variants
Number of subjects: 1129
Study 30815984 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted genetic risk score (wGRS) for CYP2A6
Number of subjects: 1129
Study 30815984 — intervention group
Group type: COMPARATOR
Intervention: CYP2A6 gene scoring approaches
Number of subjects: 1129
Study 30815984 — intervention group
Group type: EXPERIMENTAL
Intervention: NMR and C2/N2
Number of subjects: 1129
Study 30816108 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (VEGFR2 inhibitor)
Number of subjects: 64
Study 30816569 — intervention group
Group type: EXPERIMENTAL
Intervention: Getting Research into Practice model
Number of subjects: 0
Study 30816569 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical audits and situation analysis
Number of subjects: 0
Study 30816625 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha IMS device
Number of subjects: 35
Study 30816625 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha AMS device
Number of subjects: 35
Study 30816625 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both devices)
Number of subjects: 35
Study 30816809 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world therapies chosen for multiple myeloma patients
Number of subjects: 4200
Study 30816809 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world safety and healthcare resource utilization
Number of subjects: 4200
Study 30816849 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intervention (AI-powered biofeedback system, remote monitoring)
Number of subjects: 59
Study 30816849 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (face-to-face sessions)
Number of subjects: 59
Study 30817463 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h dietary recalls
Number of subjects: 0
Study 30817463 — intervention group
Group type: COMPARATOR
Intervention: 24-h urine collections
Number of subjects: 0
Study 30819010 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Mentor Dietary Intervention
Number of subjects: 0
Study 30819010 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30819173 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of Mother-Child Interaction (OMCI) measure during a 5-min picture book activity at 24 months
Number of subjects: 0
Study 30819173 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of Mother-Child Interaction (OMCI) measure controlling for HOME score
Number of subjects: 0
Study 30819173 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30819182 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization (CR, rSS = 0) in OSA patients
Number of subjects: 752
Study 30819182 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete revascularization (ICR, rSS > 0) in non-OSA patients
Number of subjects: 752
Study 30819182 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete revascularization (ICR) in OSA patients
Number of subjects: 752
Study 30819182 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) group
Number of subjects: 752
Study 30819210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (as monotherapy or add-on therapy)
Number of subjects: 0
Study 30819210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (in adults with T1D treated with continuous subcutaneous insulin infusion or multiple daily insulin injections)
Number of subjects: 0
Study 30819210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Number of subjects: 0
Study 30819368 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30819549 — intervention group
Group type: EXPERIMENTAL
Intervention: Single sub-anesthetic dose of ketamine
Number of subjects: 24
Study 30819549 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline FC between PFC and sgACC
Number of subjects: 24
Study 30819704 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated screening
Number of subjects: 15
Study 30819704 — intervention group
Group type: EXPERIMENTAL
Intervention: Health provider-initiated follow-up screening
Number of subjects: 15
Study 30819913 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusions at a threshold platelet count of 50x10^9/L
Number of subjects: 0
Study 30819913 — intervention group
Group type: COMPARATOR
Intervention: Platelet transfusions
Number of subjects: 0
Study 30820338 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion (TCI)
Number of subjects: 0
Study 30820338 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of propofol
Number of subjects: 0
Study 30820341 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit for Optimal Recovery (TOR) delivered via secure live video
Number of subjects: 54
Study 30820341 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 54
Study 30809591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal tetanus antitoxin
Number of subjects: 0
Study 30820530 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab therapy
Number of subjects: 28
Study 30820841 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 304
Study 30820841 — intervention group
Group type: EXPERIMENTAL
Intervention: SQLS Motivation subscale
Number of subjects: 304
Study 30820841 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D
Number of subjects: 304
Study 30820841 — intervention group
Group type: EXPERIMENTAL
Intervention: SQLS
Number of subjects: 304
Study 30821692 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered behavioral intervention based on social cognitive theory (SCT) with video calls from a behavioral coach for increasing physical activity in MS.
Number of subjects: 0
Study 30821692 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in detail, but monitoring plans and strategies are consistent across groups.
Number of subjects: 0
Study 30821848 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab treatment
Number of subjects: 56
Study 30822272 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg, once daily
Number of subjects: 300
Study 30822272 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin 50 mg, twice daily
Number of subjects: 300
Study 30822272 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg, once daily
Number of subjects: 300
Study 30822389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercise program (twice a week for 8 weeks)
Number of subjects: 64
Study 30822389 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical tests (DMC scale, CTTD, PLE test)
Number of subjects: 64